Letrozole
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Letrozole: From Hormone Receptor-Positive Breast Cancer to Female Breast Carcinoma
One-Sentence Summary
Letrozole is a third-generation aromatase inhibitor (AI) globally recognized as standard-of-care endocrine therapy for hormone receptor-positive (HR+) breast cancer in postmenopausal women — yet it currently holds no regulatory approval in India. The TxGNN model predicts it may be effective for female breast carcinoma with an exceptional confidence score of 99.98%, supported by 50+ clinical trials and 20 publications including multiple landmark Phase 3 RCTs. This evidence package confirms one of the most robustly validated oncology indications in modern medicine and makes a compelling case for regulatory authorization in India.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hormone receptor-positive breast cancer (postmenopausal women) — globally established; no India regulatory record |
| Predicted New Indication | Female Breast Carcinoma |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L1 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Letrozole is a potent, selective, non-steroidal aromatase inhibitor that targets the enzyme CYP19A1 (aromatase), which catalyzes the conversion of androgens (androstenedione, testosterone) to estrogens (estrone, estradiol) in peripheral tissues — including adipose tissue, muscle, and breast stroma — the primary source of estrogen in postmenopausal women. By blocking aromatase, letrozole suppresses circulating estradiol concentrations by more than 95%, effectively cutting off the hormonal signal that drives estrogen receptor-positive (ER+) breast cancer cell proliferation. This mechanism is highly selective, pharmacologically well-characterized, and has been validated across decades of clinical use worldwide.
Among all breast cancer subtypes, hormone receptor-positive tumors — which express estrogen receptors (ER) and/or progesterone receptors (PgR) — account for approximately 70–80% of all newly diagnosed cases globally, including in India. These tumors are biologically dependent on estrogen signaling for survival and proliferation, making aromatase inhibition a mechanistically direct and therapeutically rational strategy. Unlike cytotoxic chemotherapy, letrozole targets a specific hormonal pathway, which confers a substantially more tolerable long-term safety profile well suited to extended adjuvant use (5–10 years).
The TxGNN model’s prediction of letrozole for female breast carcinoma is supported by an extraordinary body of clinical evidence spanning multiple treatment settings. Landmark trials including the BIG 1-98 study (n=8,028, Letrozole vs. Tamoxifen adjuvant), the EGF30008 trial (n=1,286, Lapatinib + Letrozole in advanced disease), and the P024 neoadjuvant trial have directly validated letrozole as a cornerstone of breast cancer management in the adjuvant, neoadjuvant, and metastatic settings. Letrozole (Femara®) holds regulatory approval from the US FDA, EMA, and regulatory agencies across Asia-Pacific. The TxGNN prediction is therefore a confirmation of one of the most established therapeutic indications in oncology — with the notable gap that it is not yet formally approved in India.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00004205 | Phase 3 | Completed | 8,028 | BIG 1-98 landmark trial comparing letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with ER/PgR-positive early breast cancer; letrozole demonstrated superior disease-free survival |
| NCT00073528 | Phase 3 | Completed | 1,286 | EGF30008 trial: Lapatinib + letrozole vs. letrozole alone in HR+/HER2-positive advanced or metastatic breast cancer; letrozole served as the standard comparator arm through 2018 |
| NCT00963729 | Phase 3 | Completed | 756 | Neoadjuvant chemotherapy vs. letrozole endocrine therapy in postmenopausal patients with HR+ primary breast cancer; established the efficacy benchmark for hormonal therapy in surgical downstaging |
| NCT00330317 | Phase 3 | Completed | 300 | Multicenter study of neoadjuvant letrozole in postmenopausal HR+ primary breast cancer to enable breast-conserving surgery; assessed safety, efficacy, and optimal treatment duration |
| NCT00107016 | Phase 2 | Completed | 267 | Double-blind placebo-controlled RCT evaluating everolimus + letrozole vs. placebo + letrozole as pre-surgical therapy for newly diagnosed ER+ primary breast cancer in postmenopausal women |
| NCT04571437 | Phase 2 | Unknown | 204 | Randomized Phase II comparing letrozole with or without metronomic capecitabine as first-line treatment for ER+/HER2- advanced breast cancer; directly evaluates letrozole-based combination regimen |
| NCT02040857 | Phase 2 | Completed | 162 | Pilot feasibility study of palbociclib combined with adjuvant endocrine therapy (including letrozole) for HR+ invasive breast carcinoma; supports CDK4/6 inhibitor combination strategies |
| NCT02400567 | Phase 2 | Completed | 125 | NeoPAL trial: Letrozole + palbociclib vs. FEC-docetaxel chemotherapy as neoadjuvant treatment in PAM50 ROR-defined luminal breast cancer; demonstrated endocrine + CDK4/6i as chemotherapy alternative |
| NCT03065621 | Phase 2 | Completed | 100 | Neoadjuvant palbociclib + endocrine therapy (letrozole/fulvestrant) biomarker study in ER+/HER2- early breast cancer; characterized molecular predictors of treatment response |
| NCT05439499 | Phase 3 | Unknown | 434 | Phase III RCT evaluating FCN-437c (novel CDK4/6 inhibitor) vs. placebo in combination with letrozole or anastrozole ± goserelin in women with HR+/HER2- first-line advanced breast cancer |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16382061 | 2005 | Phase 3 RCT | New England Journal of Medicine | BIG 1-98 trial: Letrozole significantly superior to tamoxifen as adjuvant endocrine therapy for steroid hormone receptor-positive breast cancer in postmenopausal women; established letrozole as the gold standard |
| 32683565 | 2020 | Phase 2 RCT | Breast Cancer Research and Treatment | PALOMA-1 OS analysis: Palbociclib + letrozole significantly prolonged PFS vs. letrozole alone (20.2 vs. 10.2 months, HR 0.488, P=0.0004) in ER+/HER2- advanced breast cancer |
| 31838010 | 2020 | Phase 2 RCT | The Lancet Oncology | CORALLEEN trial: Ribociclib + letrozole vs. chemotherapy as neoadjuvant therapy in luminal B HR+/HER2- breast cancer; CDK4/6 inhibitor + endocrine therapy competitive with multi-agent chemotherapy |
| 15001182 | 2004 | Phase 3 RCT Analysis | Women’s Health Issues | Clinical implications of the letrozole breast cancer trial; analysis of the pivotal Phase 3 data and remaining research questions for long-term endocrine therapy |
| 35464999 | 2022 | RCT | Computational and Mathematical Methods in Medicine | Randomized comparison of sequential tamoxifen → letrozole vs. letrozole monotherapy for breast carcinoma; demonstrated superior efficacy and favorable safety of letrozole-based regimens |
| 36243120 | 2022 | Comprehensive Review | Life Sciences | Comprehensive review of letrozole pharmacology, toxicity, and therapeutic effects across adjuvant, neoadjuvant, and metastatic breast cancer settings; also covers ovulation induction use |
| 18829517 | 2008 | Clinical Study | Clinical Cancer Research | Letrozole superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels (E1, E2, E1S) in postmenopausal women with locally advanced ER/PgR+ breast cancer |
| 16500235 | 2006 | Review | Breast | Historical development of letrozole and comprehensive evidence review across advanced and neoadjuvant breast cancer settings; contextualizes letrozole’s clinical evolution |
| 17696797 | 2007 | Review | Expert Opinion on Pharmacotherapy | Letrozole’s present and future role in breast cancer: clinical implications of adjuvant trials vs. tamoxifen and the transition to aromatase inhibitors as new standard of care |
| 20095792 | 2010 | Drug Monograph | Expert Opinion on Drug Metabolism & Toxicology | Comprehensive review of letrozole pharmacodynamics, pharmacokinetics, clinical efficacy, and safety across multiple breast cancer indications |
India Market Information
Letrozole currently has no registered products in India. The drug is not marketed domestically, and no license records are available from the Indian regulatory authority (CDSCO).
Notable gap: Letrozole (Femara®) is approved for breast cancer by the US FDA, EMA (Europe), and regulatory agencies across Asia-Pacific including Japan, South Korea, and Australia. Its absence from the India market represents a significant unmet medical need, particularly given that breast cancer is the most common cancer in Indian women — and HR+ subtypes constitute the majority of cases.
Cytotoxicity
Letrozole is classified as an antineoplastic agent used in breast cancer treatment. Its mechanism is hormonal/endocrine rather than direct cytotoxicity.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted Therapy — Aromatase Inhibitor (endocrine/hormonal; non-cytotoxic mechanism) |
| Myelosuppression Risk | Low — letrozole does not directly damage bone marrow; myelosuppression is not a characteristic toxicity of this drug class |
| Emetogenicity Classification | Minimal — aromatase inhibitors are associated with very low emetogenic potential; routine antiemetic prophylaxis is not required |
| Monitoring Items | Bone mineral density (DXA scan at baseline and annually, given AI-associated bone loss risk); lipid profile; liver function tests (ALT, AST, bilirubin); blood pressure; CBC at baseline |
| Handling Protection | Standard oral medication handling applies; cytotoxic drug handling protocols are not required as letrozole is not a conventional cytotoxic chemotherapy agent |
Safety Considerations
Drug Interactions: Letrozole has 259 recorded interactions in the DDI database. The most clinically significant identified interaction is:
- Aprepitant (Moderate): Aprepitant is a CYP3A4/CYP2C9 modulator; co-administration with letrozole (metabolized via CYP3A4 and CYP2C9) may alter letrozole plasma concentrations. Monitor for changes in efficacy or tolerability when aprepitant is used as part of antiemetic regimens.
Many additional interactions — including with calcitriol, glimepiride, lansoprazole, metformin, omeprazole, prednisone, simvastatin, and morphine — are currently classified as “Unknown” severity. These warrant clinical judgment based on individual patient comorbidities and comedications.
For complete warnings, contraindications, and precaution information, please refer to the prescribing information approved in a jurisdiction where letrozole is currently authorized (e.g., Femara® FDA label or EMA SmPC). Formal India package insert data is not yet available.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Letrozole for female breast carcinoma represents one of the highest-confidence, evidence-richest indications in oncology. Multiple completed Phase 3 RCTs — including the BIG 1-98 trial (n=8,028) and EGF30008 (n=1,286) — directly validate its efficacy and safety. The TxGNN prediction score of 99.98% reflects the model correctly identifying a globally established standard of care. The primary concern is not evidence strength (L1, unambiguous) but regulatory status: letrozole is not currently approved in India, creating a meaningful market and access gap that requires formal regulatory action rather than further clinical investigation.
To proceed, the following is needed:
- CDSCO regulatory submission: Compile a global clinical dossier (BIG 1-98, PALOMA series, MONALEESA/MONARCH series, neoadjuvant trials) to support a new drug application or import registration in India
- Mechanism of action documentation (DG002): Obtain complete MOA data from DrugBank or published pharmacology references to fill the current data gap — critical for scientific dossier completeness
- India prescribing information / package insert (DG001): Source FDA or EMA-approved prescribing information to complete the safety profile; this is flagged as a Blocking data gap for S1 safety evaluation
- Bone health management protocol: Establish India-specific monitoring guidelines for AI-associated bone mineral density reduction, including DXA scanning access pathways
- Local pharmacovigilance plan: Establish adverse event reporting infrastructure for India, given the complete absence of local post-marketing safety data
- Access and affordability strategy: Evaluate generic drug availability and pricing considerations — letrozole is off-patent globally and generic formulations are widely available, which should facilitate broad access once regulatory approval is obtained in India
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.